MYMasayuki Yazawa

Masayuki Yazawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masayuki Yazawa has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Fuun Kawano

    Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA

    5 shared publications
  • Alison D. Klein

    Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA

    4 shared publications
  • Kumi Morikawa

    Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA

    4 shared publications
  • Ramsey Bekdash

    Affiliations Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, New York, United States of America, Columbia Stem Cell Initiative, Columbia University, New York, New York, United States of America, Department of Pharmacology, Columbia University, New York, New York, United States of America

    4 shared publications
  • Hannah E. Yamamoto

    Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA

    3 shared publications
  • Jose R. Quejada

    Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA

    3 shared publications

Latest Publications

  • Open Access

    Developing inhibitory peptides against SARS-CoV-2 envelope protein

    by Ramsey Bekdash, Kazushige Yoshida, Manoj S. Nair, Lauren Qiu, Johnathan Ahdout, Hsiang-Yi Tsai, Kunihiro Uryu, Rajesh K. Soni, Yaoxing Huang, David D. Ho, et al.

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the peptides that bind and inhibit E protein. Using Vero-E6 cells, human-induced pluripotent stem cell-derived branching lung organoid and mouse models with SARS-CoV-2, we found that iPep-SARS2-E significantly inhibits virus egress and reduces viral cytotoxicity and propagation in vitro and in vivo. Furthermore, the peptide can be customizable for E protein of other human coronaviruses such as Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The results indicate that E protein can be a potential therapeutic target for human coronaviruses.


  • A red light–responsive photoswitch for deep tissue optogenetics

    by Yuto Kuwasaki, Kazushi Suzuki, Gaigai Yu, Shota Yamamoto, Takahiro Otabe, Yuki Kakihara, Michiru Nishiwaki, Keita Miyake, Keiji Fushimi, Ramsey Bekdash, et al.

    Red light penetrates deep into mammalian tissues and has low phototoxicity, but few optogenetic tools that use red light have been developed. Here we present MagRed, a red light–activatable photoswitch that consists of a red light–absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin and a photo-state-specific binder that we developed using Affibody library selection. Red light illumination triggers the binding of the two components of MagRed and the assembly of split-proteins fused to them. Using MagRed, we developed a red light–activatable Cre recombinase, which enables light-activatable DNA recombination deep in mammalian tissues. We also created red light–inducible transcriptional regulators based on CRISPR–Cas9 that enable an up to 378-fold activation (average, 135-fold induction) of multiple endogenous target genes. MagRed will facilitate optogenetic applications deep in mammalian organisms in a variety of biological research areas.


  • Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome

    by LouJin Song, Ramsey Bekdash, Kumi Morikawa, Jose R. Quejada, Alison D. Klein, Danielle Aina-Badejo, Kazushige Yoshida, Hannah E. Yamamoto, Amy Chalan, Risako Yang, et al.

    Some missense gain-of-function mutations in the CACNA1C gene, encoding calcium channel CaV1.2, cause a life-threatening form of long QT syndrome (LQTS) named Timothy syndrome with currently no clinically effective therapeutics. Here we report that pharmacological targeting of sigma non-opioid intracellular receptor 1 (SIGMAR1) can restore electrophysiological function in induced pluripotent stem cell (iPSC)-derived cardiomyocytes generated from patients with Timothy syndrome and two common forms of LQTS, type 1 (LQTS1) and type 2 (LQTS2), caused by missense trafficking mutations in potassium channels. Electrophysiological recordings demonstrate that a Food and Drug Administration (FDA)-approved cough suppressant, dextromethorphan, can be used as an agonist of SIGMAR1 to shorten the prolonged action potential in cardiomyocytes from patients with Timothy syndrome and human cellular models of LQTS1 and LQTS2. When tested in vivo, dextromethorphan also normalized the prolonged QT intervals in a mouse model of Timothy syndrome. Overall, our study demonstrates that SIGMAR1 is a potential therapeutic target for Timothy syndrome and possibly other inherited arrhythmias such as LQTS1 and LQTS2.


  • Open Access

    GEM-IL: A highly responsive fluorescent lactate indicator

    by Ramsey Bekdash, Jose R. Quejada, Shunnosuke Ueno, Fuun Kawano, Kumi Morikawa, Alison D. Klein, Kenji Matsumoto, Tetz C. Lee, Koki Nakanishi, Amy Chalan, et al.


  • Open Access

    A semi-synthetic red light photoswitch for optogenetic control of protein activity

    by Yuto Kuwasaki, Kazushi Suzuki, Gaigai Yu, Yuki Kakihara, Michiru Nishiwaki, Keiji Fushimi, Ramsey Bekdash, Yoshihiro Shimizu, Rei Narikawa, Takahiro Nakajima, et al.

    Red light is useful for optogenetic control of various protein activities in mammalian deep tissues due to its high tissue penetration, low invasiveness, and low light scattering. However, technology that enables for the optogenetic manipulation using red light remains elusive. Here we develop a red light-activatable, semi-synthetic photoswitch, named MagRed. MagRed is composed of a red light-absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin, and its photo-state-specific de novo synthetic binder. MagRed allows us to reassemble split-proteins using red light and thereby develop a red light-activatable Cre recombinase, which is applicable for mammalian deep tissues. Additionally, we take advantage of MagRed to develop red light-inducible transcription system based on the CRISPR-Cas9 system, enabling for high induction (up to 378-fold) of multiple user-defined endogenous target genes. With high versatility and regulatability, MagRed provides a powerful technology that easily facilitates optogenetics applications for a variety of biological research areas.


  • Top Cited Papers

    Neuronal defects in a human cellular model of 22q11.2 deletion syndrome

    by Themasap A. Khan, Omer Revah, Aaron Gordon, Se-Jin Yoon, Anna K. Krawisz, Carleton Goold, Yishan Sun, Chul Hoon Kim, Yuan Tian, Min-Yin Li, et al.

    22q11.2 deletion syndrome (22q11DS) is a highly penetrant and common genetic cause of neuropsychiatric disease. Here we generated induced pluripotent stem cells from 15 individuals with 22q11DS and 15 control individuals and differentiated them into three-dimensional (3D) cerebral cortical organoids. Transcriptional profiling across 100 days showed high reliability of differentiation and revealed changes in neuronal excitability-related genes. Using electrophysiology and live imaging, we identified defects in spontaneous neuronal activity and calcium signaling in both organoid- and 2D-derived cortical neurons. The calcium deficit was related to resting membrane potential changes that led to abnormal inactivation of voltage-gated calcium channels. Heterozygous loss of DGCR8 recapitulated the excitability and calcium phenotypes and its overexpression rescued these defects. Moreover, the 22q11DS calcium abnormality could also be restored by application of antipsychotics. Taken together, our study illustrates how stem cell derived models can be used to uncover and rescue cellular phenotypes associated with genetic forms of neuropsychiatric disease.


  • Timothy syndrome iPSC modeling

    by Ramsey Bekdash, Alison D. Klein, Masayuki Yazawa


  • Open Access

    Perm1 regulates cardiac energetics as a downstream target of the histone methyltransferase Smyd1

    by Shin-Ichi Oka, Amira D. Sabry, Amanda K. Horiuchi, Keiko M. Cawley, Sean A. O’vEry, Maria A. Zaitsev, Thirupura S. Shankar, Jaemin Byun, Risa Mukai, Xiaoyong Xu, et al.

    The transcriptional regulatory machinery in mitochondrial bioenergetics is complex and is still not completely understood. We previously demonstrated that the histone methyltransferase Smyd1 regulates mitochondrial energetics. Here, we identified Perm1 (PPARGC-1 and ESRR-induced regulator, muscle specific 1) as a downstream target of Smyd1 through RNA-seq. Chromatin immunoprecipitation assay showed that Smyd1 directly interacts with the promoter of Perm1 in the mouse heart, and this interaction was significantly reduced in mouse hearts failing due to pressure overload for 4 weeks, where Perm1 was downregulated (24.4 ± 5.9% of sham, pNdufv1 (Complex I). Pathway enrichment analysis of cardiomyocytes in which Perm1 was knocked-down by siRNA (siPerm1), revealed that the most downregulated pathway was metabolism. Cell stress tests using the Seahorse XF analyzer showed that basal respiration and ATP production were significantly reduced in siPerm1 cardiomyocytes (40.7% and 23.6% of scrambled-siRNA, respectively, both pERRα gene and known target of ERRα, Ndufv1 (Complex I). Overall, our study demonstrates that Perm1 is an essential regulator of cardiac energetics through ERRα, as part of the Smyd1 regulatory network.


  • Open Access

    Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments

    by A. Isozaki, Y. Nakagawa, M. H. Loo, Y. Shibata, N. Tanaka, D. L. Setyaningrum, J.-W. Park, Y. Shirasaki, H. Mikami, D. Huang, et al.

    Droplet microfluidics has become a powerful tool in precision medicine, green biotechnology, and cell therapy for single-cell analysis and selection by virtue of its ability to effectively confine cells. However, there remains a fundamental trade-off between droplet volume and sorting throughput, limiting the advantages of droplet microfluidics to small droplets (Saccharomyces cerevisiae based on their growth rate.


  • Open Access

    Photoactivatable Cre recombinase 3.0 for in vivo mouse applications

    by Kumi Morikawa, Kazuhiro Furuhashi, Carmen de Sena-Tomas, Alvaro L. Garcia-Garcia, Ramsey Bekdash, Alison D. Klein, Nicholas Gallerani, Hannah E. Yamamoto, Seon-Hye E. Park, Grant S. Collins, et al.

    Optogenetic genome engineering tools enable spatiotemporal control of gene expression and provide new insight into biological function. Here, we report the new version of genetically encoded photoactivatable (PA) Cre recombinase, PA-Cre 3.0. To improve PA-Cre technology, we compare light-dimerization tools and optimize for mammalian expression using a CAG promoter, Magnets, and 2A self-cleaving peptide. To prevent background recombination caused by the high sequence similarity in the dimerization domains, we modify the codons for mouse gene targeting and viral production. Overall, these modifications significantly reduce dark leak activity and improve blue-light induction developing our new version, PA-Cre 3.0. As a resource, we have generated and validated AAV-PA-Cre 3.0 as well as two mouse lines that can conditionally express PA-Cre 3.0. Together these new tools will facilitate further biological and biomedical research.